Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

Gregory J. Riely, MD, PhD, and David S. Ettinger, MD: The What, When, and How of Biomarker Testing

Posted: Thursday, March 23, 2017

Gregory J. Riely, MD, PhD, of Memorial Sloan Kettering Cancer Center, and David S. Ettinger, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, discuss the different types of biomarkers for which effective targeted treatment is available for patients with NSCLC; the role of liquid biopsy in assessing biomarkers; and the known mechanisms for primary and secondary resistance to erlotinib, gefitinib, and afatinib.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.